2019 CYIR Finalized

23 Comments 1. Study results are highly promising if confirmed in future studies, and together with the study of BCG re-vaccination in individu- als without LTBI, may offer complementary strategies for TB control. 2. Modeling studies suggest that a TB vaccine for adults with 40-60% efficacy could reduce TB cases in low- and middle- income countries by 24-57%. 3. There is uncertain efficacy of M72 vaccine in M. tuberculosis uninfected individuals and people living with HIV (regardless of LTBI status). 4. The authors attributed the observed gender-based differ- ences in vaccine efficacy to gender imbalances across the age groups. 5. The observed differential efficacy by age and increasing vac- cine efficacy with greater time from vaccination need further investigations. TREATMENT OF TB DISEASE Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment- shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med 2018; 24: 1708-15. Summary Individualizing treatment of TB disease is desirable as the standard 6-month treatment of drug-susceptible TB (HRZE) may result in overtreatment of patients with mild disease and undertreatment of patients with severe TB. Three tri- als published in 2014 evaluated experimental 4-month fluoroquinolone-containing regimens for drug-susceptible pulmonary TB and showed that unfavorable outcomes were more common in the experimental groups compared to standard 6-month treatment. Using data from these tri- als, investigators performed an individual participant-level pooled analysis to identify characteristics associated with cure with a 4-month regimen and characteristics associ- ated with unfavorable outcomes with both experimental and standard regimens. The study included 2001 partici- pants who received fluoroquinolone-containing regimens and 1404 participants who received standard treatment. Treatment with the 4-month experimental regimens in par- ticipants with lower smear grades (<2+) or absence of radio- graphic cavities was non-inferior to the standard 6-month treatment; the smear findings were validated using results from a unique RCT. The strongest independent predictor of poor outcomes in both the experimental and standard treatment groups was medication non-adherence to >10% of prescribed doses (OR=5.8 for poor outcome). Additional independent predictors of poor outcomes included culture- positive sputum at treatment month 2, HIV-seropositivity, AFB-smear grade 3+ (compared to <2+), and low BMI. Comments 1. This study supports the need for trials to evaluate use of base- line characteristics to individualize length of treatment for drug- susceptible TB disease. 2. The strength of the associations between medication non- adherence and poor TB outcomes is novel and striking: as little as 10% non-adherence (i.e., a level of non-adherence that occurs when patients do not take their TB medications on weekends) was a strong predictor of poor outcomes. 3. It is unclear why men have an independent increased risk for poor TB outcomes and deserves further study. 4. Data was obtained from the Platform for Aggregation of Clinical TB Studies (TB-PACTS), demonstrating the importance of sharing de-identified trial data with the research community for secondary analyses. TREATMENT OF MULTIDRUG-RESISTANT TB Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D’Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Frechet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado- Laborin R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O’Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. T reatment correlates of successful outcomes in pulmonary multidrug-resistant tubercu- losis: an individual patient data meta-analysis. Lancet 2018;392(10150):821-34. Summary In 2017, only 55% of patients treated for multidrug- resistant TB (MDR-TB) were cured. The investigators performed an individual patient data meta-analysis of treatment outcomes in patients with MDR-TB and associa- tions with anti-TB drugs, number of drugs, and treatment duration. Analyses used propensity score-matched gen- eralized mixed-effects models. Eligible studies reported end of treatment outcomes for >24 adults with pulmonary MDR-TB. Fifty studies that contributed 12,030 participants were included in the meta-analysis. 61% of participants had treatment success. Treatment success was favorably MYCOBACTERIAL INFECTIONS

RkJQdWJsaXNoZXIy MTM1ODMw